(NYSE:HRB) surged 0.22% yesterday to close its trading session at $23.12. The stock stands almost -46.92% off versus the 52-week high and 4.56% away from the 52-week low. The average volume stands around 1.03 million shares. The firm shows the market capitalization of $5.04 Billion. The company reported $0.73 earnings per share for the quarter, meeting analysts' consensus estimates of $0.73. The gap between the estimate and actual number was $0.01 which created a surprise factor of 1.39%.
Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. ACHC's profit will be $61.00M for 15.00 P/E if the $0.67 EPS becomes a reality. Similarly, the company has Return on Assets of 13.7 percent, Return on Equity of -188.8 percent and Return on Investment of 29.4 Percent. (NYSE:HRB). On 26-Aug-16 Macquarie Initiated H&R Block, Inc.
On 04/28/2016, the stock reported the EPS of $0.55 where Analysts were projecting the EPS to be $0.54 showing a difference of $0.01. Of them, 8 have a "buy", 0 suggested "sell", 1 said "hold" and 0 called "underperform" rating for the stock, according to Thomson Reuters data. The analyst with the lowest target price views shares reaching $55 within the same period. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 2,138 shares in the company. (NASDAQ:ACHC) to post quarterly EPS of $0.58.
Acadia Healthcare Company, Inc.
Shares of Acadia Healthcare fell more than 7 percent after hours Tuesday following word from its executives that third-quarter results look set to fall short of analysts' expectations. Its acute inpatient psychiatric facilities offer evaluation and crisis stabilization of patients with severe psychiatric diagnoses; specialty treatment facilities include residential recovery facilities, eating disorder facilities, and comprehensive treatment centers providing a comprehensive continuum of care for adults with addictive disorders and co-occurring mental disorders; and residential treatment centers treat patients with behavioral disorders in a non-hospital setting, including outdoor programs. Acadia Healthcare Company Inc (ACHC) has declined 14.09% since March 16, 2016 and is downtrending.
In related news, CFO David M. Duckworth sold 16,670 shares of Acadia Healthcare stock in a transaction dated Monday, August 15th. The median estimate represents a +63.44% increase from the last price of 43.44. $462,536 worth of Acadia Healthcare Company Inc (NASDAQ:ACHC) was sold by Fincher Ronald Morgan. Jefferies Group reissued a buy rating and issued a $85.00 price target on shares of Acadia Healthcare in a research note on Monday, June 27th. During the same quarter in the previous year, the business posted $0.57 EPS. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell). The 5 months bearish chart indicates high risk for the $3.64B company. The company has volume of 1.53 Million shares. That's about 10.5 times their EBITDA but not enough to make Acadia whole: The local company will book a $42 million loss on the deal and write off about $107 million in goodwill. (NASDAQ:ACHC) at Last Earnings was $53.29 as compared to the previous closing price of $45.19. GlaxoSmithKline PLC has an EPS ratio of 0.02.
The company has YTD performance of -30.45 percent. The company has an average rating of "Buy" and a consensus target price of $75.86. Weekly volatility of ACHC is 4.91% and monthly volatility is 3.53%. Current price places the company's stock -28.01% away from its 200-day simple moving average, -20.05%, away from the 50-day average and also -15.25% away from 20-day average.
The Company now has ROA (Return on Assets) of 2.7 percent, Return on Equity (ROE) of 7 Percent and Return on Investment (ROI) of 5.6% with Gross margin of 0 percent and Operating & Profit margin of 14.6% and 6.2% respectively.